美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

HORIZON KINETICS MEDICAL ETF

34.96

-0.3314-0.94%

成交量：588

成交額：2.06萬

市值：1,642.82萬

市盈率：- -

高：35.04

開：34.99

低：34.96

收：35.29

52周最高：37.90

52周最低：28.87

股本：46.99萬

流通股本：46.99萬

量比：0.27

換手率：0.13%

股息：0.41

股息率：1.17%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

一品紅(300723.SZ)：痛風創新藥AR882治療痛風伴高尿酸血癥患者Ⅲ期臨床研究達到主要終點

一品紅：痛風創新藥AR882Ⅲ期臨床達主要終點

鄉村振興 | 一粒「蛋白」的農田奇遇：看盤山如何用生物科技解鎖豐收密碼

ETF日報(09.03)丨政策利好持續催化創新藥板塊「小非農」數據爆冷短期支撐金價

瑞銀上調強生目標價至320美元

寧夏銀川市市場監管局多措並舉紮實推進新版醫療器械生產質量管理規範落地實施

中国质量新闻网

創新藥概念局部回暖

A股創新藥概念局部回暖，千金藥業尾盤漲停，德展健康此前封板，諾誠健華、迪哲醫藥、百利天恒漲幅居前。

百奧賽圖與齊魯製藥達成全人納米抗體分子非排他授權合作，支持神經領域創新藥物開發

國內創新藥企中報歸母淨利增近九成！恒生創新藥ETF華泰柏瑞（520500）連續2個交易日獲資金加倉

創新藥企密集進入臨床數據驗證期，石藥集團升逾4%！華寶基金港股通創新藥ETF（520880）再收半年線！

阿斯彭押注製造業復甦和肥胖症藥物推廣以推動增長

首個國產IL-17A/F雙靶點抑制劑獲批，這一40年來「有研究無產品」的靶點迎臨床突破｜掘金創新藥

每日经济新闻

強生(JNJ)股票9月2日開盤上漲3.15%：釋放什麼信號？

TradingKey中文

創新藥半年報冰火兩重天：百濟神州一款藥賣了161億元、六成藥企還在求生，「賣藥」仍是終極命題

每日经济新闻

諾華公司：計劃停止克萊因巴塞爾生產基地的生產可能導致約130個工作崗位流失。所有計劃中的變更均需經過信息告知與協商程序。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/MEDX/news?page=13"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":34.9577,"timestamp":1789502400000,"preClose":35.2891,"halted":0,"volume":588,"delay":0,"changeRate":-0.009391001754082565,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"盤前交易","change":-0.3314,"latestTime":"09-16 08:41:31 EDT","open":34.99,"high":35.04,"low":34.9577,"amount":20606,"amplitude":0.002332,"askPrice":37,"askSize":35,"bidPrice":34.05,"bidSize":15,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":34.9577,"sharesOutstanding":569946,"nav":35.26,"aum":16570295.96,"dividendRate":0.0117,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.04,"preClose":34.9577,"latestTime":"16:10 EDT","volume":6,"amount":209.6308,"timestamp":1789503007392,"change":0.0823,"changeRate":0.002354,"amplitude":0},"volumeRatio":0.2679303977521077},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.2679303977521077,"shares":469946,"dividePrice":0.409,"high":35.04,"amplitude":0.002332,"preClose":35.2891,"low":34.9577,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":34.9577,"committee":-0.4,"eps":0,"divideRate":0.0117,"volume":588,"delay":0,"ttmEps":0,"open":34.99,"prevYearClose":33.2024,"prevWeekClose":34.9572,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":35.4213,"twentyDayClose":35.8903,"sixtyDayClose":33.8763},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:13,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664731738","title":"一品紅(300723.SZ)：痛風創新藥AR882治療痛風伴高尿酸血癥患者Ⅲ期臨床研究達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2664731738","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664731738?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:47","pubTimestamp":1788428833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红 发布公告，公司全资子公司广州瑞安博医药科技有限公司牵头组织开展的AR882胶囊治疗痛风伴高尿酸血症患者Ⅱ/Ⅲ期临床试验，于近日获得顶线分析数据。初步统计结果表明，AR882在痛风伴高尿酸血症参与者中表现出积极的疗效及良好的安全性，试验结果理想，达到预期目的。AR882克服了雷西纳德和苯溴马隆的缺点，能够与尿酸转运蛋白长效结合，延长抑制作用的时间，临床结果显示其药效长达24小时。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","300723","BK1574","MEDX","BK1161","LNGR","BK0239","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664873395","title":"一品紅：痛風創新藥AR882Ⅲ期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2664873395","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664873395?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:38","pubTimestamp":1788428306,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875833","title":"鄉村振興 | 一粒「蛋白」的農田奇遇：看盤山如何用生物科技解鎖豐收密碼","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875833","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875833?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:27","pubTimestamp":1788427620,"startTime":"0","endTime":"0","summary":"与往年不同，今年当地首次将基于蛋白质合成底层技术的生物质高蛋白营养液应用于稻蟹共生产业，为传统农业注入新质生产力。在盘山县禾壮水稻种植专业合作社的650亩稻田里，植保无人机正按照预设航线，将生物质高蛋白营养液均匀喷洒在稻叶上。合作社负责人刘壮专门划出对比试验田，用数据检验科技实效。她表示，蛋白制剂通过优化稻田水体微生态，增强水生生物免疫力，实现水稻提质、河蟹增效的双赢效果。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-03/doc-iniqpzps1035593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HBImain","BK4588","XBI","159837","GDOC","AGNG","BK4585","IBBJ","IEIH","LNGR","MEDX","SYNB","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820831","title":"ETF日報(09.03)丨政策利好持續催化創新藥板塊 「小非農」數據爆冷短期支撐金價","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664820831?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:30","pubTimestamp":1788424202,"startTime":"0","endTime":"0","summary":"国家医保局政策释放利好信号，创新药板块表现突出；美国ADP就业数据不及预期影响，黄金股相关ETF集体回升。截至收盘，恒生指数跌0.39%，报25213.31点，全日成交额1993.82亿港元；恒生科技指数跌1.08%，报4468.48点。国家医保局召开新闻发布会，发布按病种付费3.0版分组方案和技术规范，这一举措被视为对创新药板块的直接利好。因第二季净息差有所改善，信达国际短期看好内银股。中信证券表示，7月底以来，海外发达市场国债收益率普遍飙升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IAUI","YGLD","BAR","IAUM","CERY","GOAU","CEF","DULL","FGLD","CMDT","GDX","FGDL","GBUG","IAU","02840","AAAU","PYZ","SGDM","UGL","XLBI","BEGS","LNGR","OUNZ","06978","NANR","PALL","MGCmain","DGP","IBBQ","DZZ","GDE","SGOL","SHNY","USG","DBC","VGFPF","MEDX","GCmain","EPU","159992","JNUG","SGDJ","UYM","GDXD","BTGD","DUST","GLDM","SImain","RING","GDXY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802827","title":"瑞銀上調強生目標價至320美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802827","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 15:59","pubTimestamp":1788422345,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SG9999001176.SGD","XLV","SGXZ80539844.SGD","LU2505996681.GBP","LU1061106388.HKD","IE00B1BXHZ80.USD","IHE","FHLC","LU1221951046.USD","LU2430703095.HKD","UDN","LU0234570918.USD","LU2487616109.SGD","TRUH","BK4532","LU0882574055.USD","IE00BVYPNV92.GBP","LU2133065610.SGD","LU0124676726.USD","RXL","UUP","LU0070217475.USD","LU1023059063.AUD","PJP","IE000F7OJYX1.SGD","LU0683600562.USD","GDOC","SGXZ57979304.SGD","BMED","BK4007","IE000MB6IJN5.SGD","LU1244550577.SGD","FTXH","MEDX","LU0994945656.USD","LU1059921491.USD","LU1629891620.HKD","LU2112291526.USD","IE00BLSP4239.USD","BK4585","IXJ","LU1043141396.HKD","IE000BZT7R73.USD","JNJ","LU1496350502.SGD","VHT","IE00BJT1NW94.SGD","IE00BKVL7J92.USD","JDOC","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664827350","title":"寧夏銀川市市場監管局多措並舉紮實推進新版醫療器械生產質量管理規範落地實施","url":"https://stock-news.laohu8.com/highlight/detail?id=2664827350","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664827350?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 15:48","pubTimestamp":1788421680,"startTime":"0","endTime":"0","summary":"中国质量新闻网讯 2025年修订的新版《医疗器械生产质量管理规范》将于2026年11月正式施行。下一步，银川市市场监管局将全面梳理前期新规衔接推进情况及企业预检查问题台账，细化阶段性工作目标和推进举措，持续跟进企业问题整改落实进度，督促企业按期完成整改提升工作，确保新版《医疗器械生产质量管理规范》在该市平稳落地、有序施行，持续规范医疗器械生产秩序，全力守护群众用械安全。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-03/doc-iniqpvfw2067175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1583","MDEV","LGHT","PTH","AGNG","RSPH","BK1100","IEIH","MEDX","GDOC","HART","159883","09996","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664242468","title":"創新藥概念局部回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2664242468","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664242468?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:59","pubTimestamp":1788418780,"startTime":"0","endTime":"0","summary":"创新药概念局部回暖","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864003250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864003250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","LNGR","159992","BK1574","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664245108","title":"A股創新藥概念局部回暖，千金藥業尾盤漲停，德展健康此前封板，諾誠健華、迪哲醫藥、百利天恒漲幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664245108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664245108?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:58","pubTimestamp":1788418691,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664782740","title":"百奧賽圖與齊魯製藥達成全人納米抗體分子非排他授權合作，支持神經領域創新藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2664782740","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664782740?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:23","pubTimestamp":1788416580,"startTime":"0","endTime":"0","summary":"北京2026年9月3日 /美通社/ -- 百奥赛图（北京）医药科技股份有限公司于2026年9月2日宣布，公司近期与齐鲁制药有限公司签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01477","BK1161","BK1191","LNGR","BK0216","06978","MEDX","02315","688796","BK1574","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664500829","title":"國內創新藥企中報歸母淨利增近九成！恒生創新藥ETF華泰柏瑞（520500）連續2個交易日獲資金加倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2664500829","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664500829?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 13:37","pubTimestamp":1788413820,"startTime":"0","endTime":"0","summary":"全球创新药领域近期迎来密集催化。国内创新药企中报季业绩密集兑现。目前A股市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞已连续2个交易日获得资金净流入，7月以来日均成交额高达20.15亿元，最新份额、规模分别为18.99亿份、26.97亿元。华泰柏瑞基金是国内首批ETF管理人，在指数投资领域深耕超19年，为投资者打造了沪深300ETF华泰柏瑞、A500ETF华泰柏瑞等投向透明、交易便捷、费率低廉的指数工具。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpqxy2132359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","159992","MEDX","BK1574","LNGR","BK1161","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664231028","title":"創新藥企密集進入臨床數據驗證期，石藥集團升逾4%！華寶基金港股通創新藥ETF（520880）再收半年線！","url":"https://stock-news.laohu8.com/highlight/detail?id=2664231028","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664231028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 10:52","pubTimestamp":1788403920,"startTime":"0","endTime":"0","summary":"9月3日，港股创新药链继续活跃，创新药龙头公司领涨，石药集团、中国生物制药双双涨超4%。纯正创新药指数——恒生港股通创新药精选指数一度冲高逾2%，跟踪该指数的港股通创新药ETF华宝盘中再收半年线。中金公司提示，创新药较多公司进入临床数据验证阶段，值得自下而上关注。据统计，港股通创新药ETF华宝覆盖的48家创新药研发公司中，31家上半年实现盈利，归母净利同比正增长的有33家，占比近7成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-03/doc-iniqpkry1034045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","IE0008368742.USD","FLHK","IE00B543WZ88.USD","LU1226287792.SGD","LU1226288170.HKD","LU2039709279.SGD","BK1574","LNGR","520880","LU0315179316.USD","LU1951186391.HKD","BK1191","HK0000165453.HKD","IE00B5MMRT66.SGD","LU1226287875.USD","06978","LU0501845795.SGD","KURE","LU0314109678.HKD","LU1152091168.USD","MEDX","LU1807302812.USD","IE00B031HY20.USD","LU0140636845.USD","LU0326950275.SGD","LU1328277881.USD","BK1521","01093","IE00BZ08YT58.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1226288253.USD","LU1960683339.HKD","LU1152091754.HKD","SG9999004220.SGD","IE00BZ08YS42.EUR","159992","LU0072913022.USD","IBBQ","159316","LU0067412154.USD","LU1226287529.USD","IE0008369823.USD","LU1993786604.SGD","BK1161","LU0880133367.SGD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487728","title":"阿斯彭押注製造業復甦和肥胖症藥物推廣以推動增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487728","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487728?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 00:16","pubTimestamp":1788365816,"startTime":"0","endTime":"0","summary":"他补充道，阿斯彭的目标市场包括南非、包括巴西在内的拉丁美洲部分地区以及中东，具体上市时间取决于监管审批。集团营收持平于349亿兰特，这是因为其商业制药业务的增长抵消了因失去mRNA合同而导致的制造业务销售额下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4S44U1IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004445239.USD","TMED","IE00BK4W5L77.USD","LU2471134879.HKD","LU1093756168.USD","SG9999014898.SGD","LU0203201768.USD","LU1267930730.SGD","SG9999015978.USD","LU0345770308.USD","IE00BK4W5M84.HKD","LU1974910355.USD","LU2896262040.SGD","LU0109391861.USD","LU0385154629.USD","LU0787776722.HKD","LU1280957306.USD","LU2168564149.EUR","LU2357305700.SGD","MEDX","BK4585","LU0823434740.USD","LU2361044865.SGD","IE00BKDWB100.SGD","LU0289739699.SGD","LU0096364046.USD","SG9999001176.SGD","LU2211815571.USD","BK4516","LU2471134523.USD","LU2462157665.USD","SG9999014914.USD","LU0158827781.USD","LU0432979614.USD","IE0005OL40V9.USD","LU0097036916.USD","LU0471298777.SGD","LU1061106388.HKD","IE00B4R5TH58.HKD","LU0058720904.USD","SG9999013999.USD","LU2602419157.SGD","LU0353189763.USD","LU0094547139.USD","LU0320765992.SGD","BK4007","LU2361044949.HKD","LU0466842654.USD","CURE","LU2324357040.USD","LU1720051017.SGD","LU2168564222.USD","BK4534","LLYZ","JDOC","IHE","LU0882574055.USD","XLV","LU1868836591.USD","IE00BJT1NW94.SGD","LU0823416689.USD","LU2087625088.SGD","LU2168564065.EUR","IE00BWXC8680.SGD","IE00BFTCPJ56.SGD","LU2264538146.SGD","LU0225283273.USD","TRUH","LU0210536198.USD","IE00BKPKM429.USD","LU2756315664.SGD","LU0158827948.USD","LU0820562030.AUD","CANC","LU1868837136.USD","SG9999018857.SGD","LU0354030438.USD","LU1548497426.USD","LU2237443465.HKD","LU2746668461.USD","LU0456855351.SGD","LU2456880835.USD","IE00B775H168.HKD","LU0203202063.USD","LU2237438978.USD","IE00BJLML261.HKD","IE00BFSS8Q28.SGD","PJP","ELIL","LU0061475181.USD","LU1868837300.USD","LU2089283258.USD","LU2491050154.USD","LU2756315318.SGD","LU1064131342.USD","LU0079474960.USD","LU0106261372.USD","LU2468319806.SGD","LU1035775433.USD","LU1988902786.USD","LU2108987350.USD","LU1712237335.SGD","LU2089284900.SGD","LU2237443978.SGD","IE00BJJMRZ35.SGD","BK4581","SGXZ57979304.SGD","LU0174119429.USD","LU0256863811.USD","LU1917777945.USD","LU0820561818.USD","LU2237443622.USD","LU0109394709.USD","LU2471134952.CNY","LU1291159041.SGD","LU1983299246.USD","MEDI","IXJ","LU1868836757.USD","LU2361045086.USD","IE0004445015.USD","SG9999015952.SGD","LU0943347566.SGD","LU1069344957.HKD","LU0689472784.USD","IE00BJJMRX11.SGD","LU1323610961.USD","LU0672654240.SGD","LU1232071149.USD","LLYX","LU2236285917.USD","IE0001KFT4U8.USD","LU2112291526.USD","LU0708995401.HKD","IE00B1XK9C88.USD","SGXZ51526630.SGD","LU2552382215.SGD","LU2265009873.SGD","IE00BJJMRY28.SGD","LU1720051108.HKD","LU0820561909.HKD","LU1989771016.USD","LU2089984988.USD","AGNG","LU2237443549.SGD","PPH","LU2746668974.SGD","LU0006306889.USD","LU2237443895.HKD","RXL","SG9999014880.SGD","LU2213496289.HKD","LU1366192091.USD","LLY","LU0823434583.USD","LU0122379950.USD","SG9999015945.SGD","LU0353189680.USD","BK4599","LU1551013425.SGD","IE00B4JS1V06.HKD","LU1551013342.USD","LU2491049909.HKD","LU1868836914.USD","LU2063271972.USD","FTXH","LU2111349929.HKD","LU2417539215.USD","IYH","THNR","LU2461242641.AUD","IE0002141913.USD","IE00BFSS7M15.SGD","LU0266013472.USD","LU2023250504.SGD","LU1804176565.USD","LU0889565916.HKD","ILDR","LU0238689110.USD","LU1145028129.USD","LU0114720955.EUR","SG9999001176.USD","WDNA","LU2360106947.USD","SGXZ31699556.SGD","LU0417517546.SGD","LU2271345857.HKD","LU0133085943.USD","IE0009355771.USD","LU2028103732.USD","LU0786609619.USD","LU1127390331.HKD","LU1691799644.USD","LU2750360997.AUD","LU1814569148.SGD","LU1629891620.HKD","LU2462591350.SGD","SG9999014906.USD","IE00B7KXQ091.USD","LU0471298694.HKD","LU0683600562.USD","LU2023251221.USD","LU2237443382.USD","LU0345770993.USD","LU1093756325.SGD","LU2750360641.GBP","SG9999018865.SGD","SGXZ81514606.USD","BK4533","LU2552382132.HKD","LU2023250330.USD","LU0882574139.USD","LU2491050071.SGD","BK4588","OZEM","LU0354030511.USD","IE00BN29S564.USD","LU2471134796.USD","LU1057294990.SGD","LU0234572021.USD","LU0316494557.USD","LU1023059063.AUD","LU2168563687.JPY","HRTS","ELIS","LU1623119135.USD","SG9999015986.USD","LU0640476718.USD","LU0256863902.USD","LU2106854487.HKD","SGXZ99366536.SGD","GB00BDT5M118.USD","LLII","LU2552382058.USD","IE00B1BXHZ80.USD","MHIP","LU1979441026.SGD","LU0323591593.USD","LU0964807845.USD","IE00B2B36J28.USD","VHT","LU0198837287.USD","LU0320765059.SGD","FHLC","LU2168564495.EUR","SG9999017495.SGD","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810334","title":"首個國產IL-17A/F雙靶點抑制劑獲批，這一40年來「有研究無產品」的靶點迎臨床突破｜掘金創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810334","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664810334?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 22:37","pubTimestamp":1788359868,"startTime":"0","endTime":"0","summary":"半月临床试验动向根据医药魔方提供的数据，8月15日至8月28日，国家药品监督管理局药品审评中心（CDE）共披露195条创新药临床试验登记信息，其中53条为Ⅱ期及以上的关键临床试验。8月15日至8月28日，国家药品监督管理局批准8款创新药上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023863103683.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023863103683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","LNGR","06978","MEDX","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664179318","title":"強生(JNJ)股票9月2日開盤上漲3.15%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664179318","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664179318?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 21:48","pubTimestamp":1788356898,"startTime":"0","endTime":"0","summary":"• 资金向医疗保健股等防御性板块轮动，推动强生股价上涨。\n• 滑石粉诉讼的进展与 FDA 批准提振了投资者信心，并助力其增长战略。\n• 公司公布了强劲的季度业绩，并上调了全年运营指引。","market":"hk","thumbnail":"https://resource.tradingkey.com/uploads/20250314/d38d57c8dfb24421a5b88ef27a9554e3shutterstock_2383470839_optimized_150.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20250314/d38d57c8dfb24421a5b88ef27a9554e3shutterstock_2383470839_optimized_150.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262146572-market-movers-jnj-20260902","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250330.USD","BK4007","LU1228905540.USD","RXL","LU0545562505.USD","JNJ","BK4550","LU1914381329.SGD","VHT","IE0002141913.USD","LU1894683264.USD","LU2896262040.SGD","BK4559","IE0009355771.USD","IE00B1BXHZ80.USD","IYH","LU1057294990.SGD","LU0882574055.USD","LU2129689431.USD","LU0820561909.HKD","MEDX","PJP","BK4532","FTXH","LU2592432038.USD","XLV","IE000MB6IJN5.SGD","IE00BN8TJ469.HKD","GDOC","JDOC","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU1674673428.USD","LU1032955483.USD","IXJ","LU1430594728.SGD","IE00BGHQF631.EUR","LU1196500208.SGD","LU1121112475.USD","LU0345769128.USD","TRUH","IHE","LU1585245621.USD","LU2471134796.USD","FHLC","LU1718418525.SGD","LU2756315664.SGD","LU0426412945.USD","BMED","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664081495","title":"創新藥半年報冰火兩重天：百濟神州一款藥賣了161億元、六成藥企還在求生 ，「賣藥」仍是終極命題","url":"https://stock-news.laohu8.com/highlight/detail?id=2664081495","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664081495?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:48","pubTimestamp":1788353325,"startTime":"0","endTime":"0","summary":"2026年上半年财报季收官，中国创新药产业交出了一份分水岭式的答卷。行业正在告别烧钱讲故事的阶段，走向赚钱才是硬道理的价值兑现期。这种转变并非行业普涨，而是由商业化放量、出海授权爆发、资金来源多元化三重动力共同推动的分化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862982990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862982990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1303224171.USD","MEDX","KURE","LU0828237510.HKD","LU0588546209.SGD","LU0228659784.USD","BK0239","06978","BK4585","06160","LNGR","BK1583","LU1969619763.USD","LU0307460666.USD","BK4139","BK4588","688235","IBBQ","BK1574","LU1251922891.USD","BK1161","LU1770034418.SGD","LU1719994722.HKD","BK1500","ONC","BK1588","159992","LU2328871848.SGD","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811784","title":"諾華公司：計劃停止克萊因巴塞爾生產基地的生產可能導致約130個工作崗位流失。所有計劃中的變更均需經過信息告知與協商程序。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811784","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811784?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:37","pubTimestamp":1788352638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","MEDX","BK4588","IE0002141913.USD","LU0208291251.USD","BK4585","LU0320765489.SGD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4532","LU0070302665.USD","IE0009355771.USD","BK4007","PPH","BK4578","IE00B2B36J28.USD","NVS","HELS","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":13,"totalSize":256,"code":"91000000","status":"200"}]}}